Sanofi, GSK to supply vaccine doses to WHO-backed alliance

FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs

PARIS (Reuters) - French drugmaker Sanofi and Britain's GlaxoSmithKline will supply 200 million doses of their COVID-19 candidate vaccine to a global inoculation scheme backed by the World Health Organization.

There is no internationally-approved treatment against COVID-19, which has killed more than 1.16 million people, and the two companies' vaccine is still undergoing phase 1 and 2 trials, from which first results are expected by late November or early December.